search
Back to results

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)

Primary Purpose

Locally Advanced Solid Tumors, Metastatic Solid Tumors

Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
Oral repotrectinib (TPX-0005)
Sponsored by
Turning Point Therapeutics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Locally Advanced Solid Tumors focused on measuring ALK, ROS1, NTRK, Sarcoma, Lung Neoplasms, Carcinoma, NSCL, NSCLC, Non Small Cell Lung, Thyroid Disease, Colonic Neoplasms, Thyroid Neoplasms, Carcinoma, Neuroendocrine, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Disease, Respiratory Tract Disease, Carcinoma, Bronchogenic, Bronchial Neoplasms, Endocrine System Disease, Colorectol Neoplasms, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Gastrointestinal Disease, Colonic Disease, Intestinal Disease, Endocrine Gland Neoplasms, Head and Neck Neoplasms, Neuroendocrine Tumors, Neuroectodermal Tumors, Neoplasms, Germ Cell and Embryonal, Neoplasms by Histologic Type, Adenocarcinoma, Non Small Cell Lung Cancer, Solid Tumors, Rearrangements, TRIDENT-1, TKI, TKI naive, TKI pretreated, Anti-tumor activity, Repotrectinib, Advanced Solid Malignancies

Eligibility Criteria

12 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

PHASE 1

Key Inclusion Criteria:

  1. Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic solid tumor (including primary CNS tumors) (Stage IV, American Joint Committee on Cancer v.7) that harbors an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement by protocol specified tests.
  2. ECOG PS 0-1.
  3. Age ≥18 (or age ≥ 20 of age as required by local regulation).
  4. Capability to swallow capsules intact (without chewing, crushing, or opening).
  5. At least 1 measurable target lesion according to RECIST version 1.1. CNS-only measurable disease as defined by RECIST version 1.1 is allowed.
  6. Prior cytotoxic chemotherapy is allowed.
  7. Prior immunotherapy is allowed.
  8. Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 Grade less than or equal to 1.
  9. Patients with asymptomatic CNS metastases (treated or untreated) and/or asymptomatic leptomeningeal carcinomatosis are eligible to enroll if they satisfy the protocol specified criteria.
  10. Baseline laboratory values fulfilling the following requirements:Absolute neutrophils count (ANC) ≥1500/mm3 (1.5 × 109/L); Platelets (PLTs) ≥100,000/mm3 (100 × 109/L); Hemoglobin ≥ 9.0 g/dL transfusions are allowed; Serum creatinine or creatinine clearance Within normal limits or > 40 mL/min; Total serum bilirubin < 1.5 × ULN; Liver transaminases (ASTs/ALTs) < 2.5 × ULN; < 5 × ULN if liver metastases are present Alkaline phosphatase (ALP); < 2.5 × ULN; < 5 × ULN if liver and/or bone metastasis are present; Serum calcium, magnesium, and potassium Normal or CTCAE grade ≤ 1 with or without supplementation
  11. Life expectancy ≥ 3 months.

PHASE 2 Key Inclusion Criteria

  1. Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic solid tumor (including primary CNS tumors) that harbors a ROS1, or NTRK1-3 gene fusion.
  2. Subject must have a documented ROS1 or NTRK1-3 gene fusion determined by tissue-based local testing using either:

    1. a next-generation sequencing (NGS) or quantitative polymerase chain reaction (qPCR) test will be accepted to determine molecular eligibility.

      • Adequate tumor tissue needs to be sent to the Sponsor designated central diagnostic laboratory for retrospective confirmation by a central diagnostic laboratory test selected by the Sponsor.

      OR

    2. a fluorescence in situ hybridization (FISH) test AND prospective confirmation of fusion status by a central diagnostic laboratory test selected by the Sponsor PRIOR to enrollment will be accepted to determine molecular eligibility.

      • Adequate tumor tissue must be sent to the Sponsor designated central diagnostic laboratory for prospective confirmation by a central diagnostic laboratory test selected by the Sponsor PRIOR to enrollment.
  3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.
  4. Age ≥12 (or age ≥ 20 as required by local regulation).
  5. Willing and able to provide written institutional review board (IRB)/institutional ethics committee-approved Informed Consent or an Assent signed by a parent or legal guardian for subjects age 12 to 17.
  6. At least 1 measurable target lesion according to RECIST (v1.1) prospectively confirmed by Blinded Independent Central Radiology Review (BICR), selected by Sponsor, PRIOR to enrollment. Subjects with CNS-only measurable disease ≥10 mm as defined by RECIST (v1.1) are eligible.
  7. Subjects with advanced solid tumors harboring ROS1, NTRK1, NTRK2, or NTRK3 rearrangement will be assigned into 6 distinct expansion (EXP) cohorts provided all inclusion and exclusion criteria are met.

    i. EXP-1: ROS1 TKI-naïve ROS1+ NSCLC ii. EXP-2: 1 Prior ROS1 TKI and 1 Platinum based chemo ROS1+ NSCLC iii. EXP-3: 2 Prior ROS1 TKIs ROS1+ NSCLC (No Chemo or IO) iv. EXP-4: 1 Prior ROS1 TKI ROS1+ NSCLC (No Chemo or IO) v. EXP-5: TRK TKI-naïve NTRK+ solid tumors vi. EXP-6: TRK TKI-pretreated NTRK+ solid tumors

  8. Subjects with asymptomatic CNS metastases (treated or untreated) and/or asymptomatic leptomeningeal carcinomatosis are eligible to enroll if they satisfy the protocol specified criteria.
  9. Baseline laboratory values fulfilling the following requirements:Absolute neutrophils count (ANC) ≥1500/mm3 (1.5 × 109/L); Platelets (PLTs) ≥100,000/mm3 (100 × 109/L); Hemoglobin ≥ 9.0 g/dL transfusions are allowed; Serum creatinine or creatinine clearance > 40 mL/min; Total serum bilirubin < 1.5 × ULN; Liver transaminases (ASTs/ALTs) < 2.5 × ULN; < 5 × ULN if liver metastases are present Alkaline phosphatase (ALP); < 2.5 × ULN; < 5 × ULN if liver and/or bone metastasis are present; Serum calcium, magnesium, and potassium Normal or CTCAE grade ≤ 1 with or without supplementation
  10. Life expectancy ≥ 3 months.

Key Exclusion Criteria PHASE 1 and PHASE 2

  1. Concurrent participation in another therapeutic clinical trial.
  2. Symptomatic brain metastases or leptomeningeal involvement.
  3. History of previous cancer, except for squamous cell or basal-cell carcinoma of the skin, or any in situ carcinoma that has been completely resected, requiring therapy within the previous 2 years.
  4. Major surgery within 4 weeks of start of repotrectinib treatment. Radiation therapy (except palliative to relieve bone pain) within 2 weeks of study entry. Palliative radiation (≤10 fractions) must have been completed at least 48 hours prior to study entry
  5. Clinically significant cardiovascular disease (either active or within 6 months prior to enrollment): myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (New York Heart Association Classification Class ≥ II), cerebrovascular accident or transient ischemic attack, symptomatic bradycardia, requirement for anti-arrhythmic medication. Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥2
  6. Any of the following cardiac criteria:

    Mean resting corrected QT interval (ECG interval measured from the onset of the QRS complex to the end of the T wave) for heart rate (QTcF) > 470 msec obtained from 3 ECGs, using the screening clinic ECG machine-derived QTc value Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block, PR interval > 250 msec) Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or any concomitant medication known to prolong the QT interval.

  7. Known active infections (bacterial, fungal, viral including HIV positivity).
  8. Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact drug absorption.
  9. Peripheral neuropathy of CTCAE ≥grade 2.
  10. History of extensive, disseminated, bilateral, or presence of CTCAE grade 3 or 4 interstitial fibrosis or interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, and pulmonary fibrosis. Subjects with history of prior radiation pneumonitis are not excluded.

Sites / Locations

  • City Of HopeRecruiting
  • Adventist Health GlendaleRecruiting
  • UC San Diego HealthRecruiting
  • Pacific Shores Medical GroupRecruiting
  • UC Irvine Medical CenterRecruiting
  • St Joseph Heritage HealthcareRecruiting
  • University Of Colorado DenverRecruiting
  • Georgetown University Medical Center - Lombardi Comprehensive Cancer CenterRecruiting
  • The Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsRecruiting
  • Memorial Healthcare SystemRecruiting
  • Moffitt Cancer CenterRecruiting
  • University Cancer and Blood CenterRecruiting
  • Colombus Regional Research InstituteRecruiting
  • University of ChicagoRecruiting
  • Illinois Cancer CareRecruiting
  • University of Maryland Medical CenterRecruiting
  • Massachusetts General Hospital,Recruiting
  • Dana Farber Cancer Institute.Recruiting
  • University Of MichiganRecruiting
  • Karmanos Cancer InstituteRecruiting
  • Henry Ford Transplant InstituteRecruiting
  • Regions Hospital - Cancer Care CenterRecruiting
  • Central Care Cancer CenterRecruiting
  • Washington University Infusion Center PharmacyRecruiting
  • Rutgers Cancer Institute of New JerseyRecruiting
  • Laura & Isaac Perlmutter Cancer CenterRecruiting
  • Memorial Sloan Kettering Cancer CenterRecruiting
  • Southeastern Medical Oncology CenterRecruiting
  • Gabrail Cancer CenterRecruiting
  • Trihealth Cancer InstituteRecruiting
  • Cleveland Clinic Main CampusRecruiting
  • The Ohio State University Wexner Medical CenterRecruiting
  • Fox Chase Cancer CenterRecruiting
  • Baptist Memorial Hospital Baptist Cancer CenterRecruiting
  • UT Southwestern Medical CenterRecruiting
  • MD Anderson Cancer CenterRecruiting
  • Oncology Consultants, P.A.Recruiting
  • Lumi ResearchRecruiting
  • Virginia Cancer Specialists, PCRecruiting
  • University of Washington-Seattle Cancer Care AllianceRecruiting
  • ThedaCareRecruiting
  • Local Institution - 6102Recruiting
  • Local Institution - 6103Recruiting
  • Local Institution - 6101Recruiting
  • Local Institution - 4802Recruiting
  • Local Institution - 4801Recruiting
  • Local Institution - 2202Recruiting
  • Local Institution - 2205
  • Local Institution - 2201Recruiting
  • Local Institution - 6503Recruiting
  • Local Institution - 2203Recruiting
  • Local Institution - 2204Recruiting
  • Local Institution - 6702Recruiting
  • Local Institution - 6703Recruiting
  • Local Institution - 6736Recruiting
  • Local Institution - 6719Recruiting
  • Local Institution - 6708Recruiting
  • Local Institution - 6733Recruiting
  • Local Institution - 6747Recruiting
  • Local Institution - 6505Recruiting
  • Local Institution - 6722Recruiting
  • Local Institution - 6504Recruiting
  • Local Institution - 6705Recruiting
  • Local Institution - 6718Recruiting
  • Local Institution - 6748Recruiting
  • Local Institution - 6732Recruiting
  • Local Institution - 6714Recruiting
  • Local Institution - 6742Recruiting
  • Local Institution - 6754Recruiting
  • Local Institution - 6749Recruiting
  • Local Institution - 6728Recruiting
  • Local Institution - 6716Recruiting
  • Local Institution - 6725Recruiting
  • Local Institution - 6721Recruiting
  • Local Institution - 6717Recruiting
  • Local Institution - 6720Recruiting
  • Local Institution - 6734Recruiting
  • Local Institution - 6724Recruiting
  • Local Institution - 6712Recruiting
  • Local Institution - 6704Recruiting
  • Local Institution - 6701Recruiting
  • Local Institution - 6709Recruiting
  • Local Institution - 6727Recruiting
  • Local Institution - 6710Recruiting
  • Local Institution - 6715Recruiting
  • Local Institution - 4901Recruiting
  • Local Institution - 4201Recruiting
  • Local Institution - 4207Recruiting
  • Local Institution - 4204Recruiting
  • Local Institution - 4206Recruiting
  • Local Institution - 4205Recruiting
  • Local Institution - 4208Recruiting
  • Local Institution - 4203Recruiting
  • Local Institution - 4202Recruiting
  • Local Institution - 4704Recruiting
  • Local Institution - 4703Recruiting
  • Local Institution - 4702Recruiting
  • Local Institution - 4701Recruiting
  • Local Institution - 6502Recruiting
  • Local Institution - 6501Recruiting
  • Local Institution - 5101Recruiting
  • Local Institution - 5103Recruiting
  • Local Institution - 4301Recruiting
  • Local Institution - 4306Recruiting
  • Local Institution - 4307
  • Local Institution - 4303Recruiting
  • Local Institution - 4305Recruiting
  • Local Institution - 4308Recruiting
  • Local Institution - 4302Recruiting
  • Local Institution - 6609Recruiting
  • Local Institution - 6607Recruiting
  • Local Institution - 6603Recruiting
  • Local Institution - 6605Recruiting
  • Local Institution - 6604Recruiting
  • Local Institution - 6606Recruiting
  • Local Institution - 6601Recruiting
  • Local Institution - 6608Recruiting
  • Local Institution - 6602Recruiting
  • Local Institution - 6305Recruiting
  • Local Institution - 6308Recruiting
  • Local Institution - 6301Recruiting
  • Local Institution - 6303Recruiting
  • Local Institution - 6306Recruiting
  • Local Institution - 6302Recruiting
  • Local Institution - 6307Recruiting
  • Local Institution - 6304Recruiting
  • Local Institution - 4502Recruiting
  • Local Institution - 4501Recruiting
  • Local Institution - 4601Recruiting
  • Local Institution - 4604Recruiting
  • Local Institution - 4605Recruiting
  • Local Institution - 4603Recruiting
  • Local Institution - 4602Recruiting
  • Local Institution - 6401Recruiting
  • Local Institution - 6402Recruiting
  • Local Institution - 4102Recruiting
  • Local Institution - 4101Recruiting
  • Local Institution - 4106Recruiting
  • Local Institution - 4104Recruiting
  • Local Institution - 4103Recruiting
  • Local Institution - 4105Recruiting
  • Local Institution - 4108Recruiting
  • Local Institution - 4107Recruiting
  • Local Institution - 6201Recruiting
  • Local Institution - 6203Recruiting
  • Local Institution - 6202Recruiting
  • Local Institution - 4401Recruiting
  • Local Institution - 4402Recruiting
  • Local Institution - 4404Recruiting
  • Local Institution - 4403Recruiting
  • Local Institution - 4405Recruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Repotrectinib (TPX-0005)

Arm Description

Phase 1 Oral repotrectinib (TPX-0005): Phase 1a dose escalation, Phase 1b food-effect sub-study, and Phase 1c dose escalation with food, and Midazolam drug-drug interaction sub-study. Phase 2 Oral repotrectinib (TPX-0005): 6 distinct expansion cohorts EXP-1: ROS1 TKI-naïve ROS1+ NSCLC EXP-2: 1 Prior ROS1 TKI and 1 Platinum based chemo ROS1+ NSCLC EXP-3: 2 Prior ROS1 TKIs ROS1+ NSCLC (No Chemo or IO) EXP-4: 1 Prior ROS1 TKI ROS1+ NSCLC (No Chemo or IO) EXP-5: TRK TKI-naïve NTRK+ solid tumors EXP-6: TRK TKI-pretreated NTRK+ solid tumors

Outcomes

Primary Outcome Measures

Dose limiting toxicities (DLTs) (Phase 1)
Define the dose limiting toxicities (DLTs) (Phase 1)
Recommended Phase 2 Dose (RP2D) (Phase 1)
To determine the RP2D (Phase 1)
Overall Response Rate (ORR) Phase 2
To determine the confirmed ORR of repotrectinib (TPX-0005) as assessed by Blinded Independent Central Review (Phase 2)

Secondary Outcome Measures

Maximum plasma concentration (CMAX) of repotrectinib (TPX-0005) (Phase 1)
To determine the maximum plasma concentration (CMAX) of repotrectinib (TPX-0005)
Area under the plasma concentration time curve (AUC) of repotrectinib (TPX-0005) (Phase 1)
To determine the area under the plasma concentration time curve (AUC) of repotrectinib
Area under the plasma concentration time curve (AUC) of repotrectinib under different food intake conditions(TPX-0005) (Phase 1)
To determine the area under the plasma concentration time curve (AUC) of repotrectinib under different food intake conditions(TPX-0005) (Phase 1)
Maximum plasma concentration (CMAX) of repotrectinib under different food intake conditions(TPX-0005) (Phase 1)
To determine the maximum plasma concentration (CMAX) of repotrectinib under different food intake conditions(TPX-0005) (Phase 1)
Area under the plasma concentration time curve (AUC) of midazolam(TPX-0005) (Phase 1)
To determine the area under the plasma concentration time curve (AUC) of midazolam(TPX-0005) (Phase 1)
Maximum plasma concentration (CMAX) of midazolam(TPX-0005) (Phase 1)
To determine the maximum plasma concentration (CMAX) of midazolam(TPX-0005) (Phase 1)
Plasma concentration of repotrectinib following administration at RP2D (Phase 2)
To evaluate the plasma concentration of repotrectinib following administration at RP2D (Phase 2)
Preliminary objective response rate (ORR) (Phase 1)
To determine the preliminary objective response rate (ORR) by Blinded Independent Central Review (BICR) (Phase 1)
Duration of response (DOR) (Phase 2)
To determine the DOR of repotrectinib (TPX-0005) (Phase 2)
Clinical benefit rate (CBR) (Phase 2)
To determine the CBR of repotrectinib (TPX-0005) (Phase 2)
Progression free survival (PFS) (Phase 2)
To determine the PFS (Phase 2)
Overall survival (OS) (Phase 2)
To determine the OS (Phase 2)
Intracranial objective response rate (Phase 2)
To determine the intracranial objective response rate (Phase 2)

Full Information

First Posted
March 6, 2017
Last Updated
August 11, 2023
Sponsor
Turning Point Therapeutics, Inc.
Collaborators
Zai Lab (Shanghai) Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT03093116
Brief Title
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Acronym
TRIDENT-1
Official Title
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
February 27, 2017 (Actual)
Primary Completion Date
June 30, 2024 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Turning Point Therapeutics, Inc.
Collaborators
Zai Lab (Shanghai) Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary objective will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.
Detailed Description
In Phase 2, study subjects will be enrolled into 6 distinct expansion (EXP) cohorts: EXP-1: ROS1 TKI-naïve ROS1+ NSCLC. Up to one prior line of chemotherapy OR immunotherapy is allowed EXP-2: 1 Prior ROS1 TKI AND 1 Platinum-based Chemotherapy ROS1+ NSCLC. Disease progression, or intolerant to one prior line of a ROS1 TKI. Must have received one prior line of platinum based chemotherapy OR one prior line of platinum based chemotherapy in combination with immunotherapy before or after a ROS1 TKI EXP-3: 2 Prior ROS1 TKIs AND NO Chemotherapy ROS1+ NSCLC. Disease progression, or intolerant to 2 prior lines of a ROS1 TKI treatment. No prior lines of chemotherapy or immunotherapy are allowed. EXP-4: 1 Prior ROS1 TKI and NO Chemotherapy or Immunotherapy. Disease progression or intolerant to one prior line of a ROS1 TKI. No prior lines of chemotherapy or immunotherapy are allowed. EXP-5: TRK TKI-naïve NTRK+ solid tumors. Any number of prior lines of chemo or immunotherapy is allowed. EXP-6: TRK TKI-pretreated NTRK+ solid tumors. Disease progression, or intolerant to 1 or 2 prior TRK TKIs. Any number of prior lines of chemo- or immunotherapy are allowed.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Locally Advanced Solid Tumors, Metastatic Solid Tumors
Keywords
ALK, ROS1, NTRK, Sarcoma, Lung Neoplasms, Carcinoma, NSCL, NSCLC, Non Small Cell Lung, Thyroid Disease, Colonic Neoplasms, Thyroid Neoplasms, Carcinoma, Neuroendocrine, Respiratory Tract Neoplasms, Thoracic Neoplasms, Neoplasms by Site, Neoplasms, Lung Disease, Respiratory Tract Disease, Carcinoma, Bronchogenic, Bronchial Neoplasms, Endocrine System Disease, Colorectol Neoplasms, Intestinal Neoplasms, Gastrointestinal Neoplasms, Digestive System Neoplasms, Gastrointestinal Disease, Colonic Disease, Intestinal Disease, Endocrine Gland Neoplasms, Head and Neck Neoplasms, Neuroendocrine Tumors, Neuroectodermal Tumors, Neoplasms, Germ Cell and Embryonal, Neoplasms by Histologic Type, Adenocarcinoma, Non Small Cell Lung Cancer, Solid Tumors, Rearrangements, TRIDENT-1, TKI, TKI naive, TKI pretreated, Anti-tumor activity, Repotrectinib, Advanced Solid Malignancies

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
500 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Repotrectinib (TPX-0005)
Arm Type
Experimental
Arm Description
Phase 1 Oral repotrectinib (TPX-0005): Phase 1a dose escalation, Phase 1b food-effect sub-study, and Phase 1c dose escalation with food, and Midazolam drug-drug interaction sub-study. Phase 2 Oral repotrectinib (TPX-0005): 6 distinct expansion cohorts EXP-1: ROS1 TKI-naïve ROS1+ NSCLC EXP-2: 1 Prior ROS1 TKI and 1 Platinum based chemo ROS1+ NSCLC EXP-3: 2 Prior ROS1 TKIs ROS1+ NSCLC (No Chemo or IO) EXP-4: 1 Prior ROS1 TKI ROS1+ NSCLC (No Chemo or IO) EXP-5: TRK TKI-naïve NTRK+ solid tumors EXP-6: TRK TKI-pretreated NTRK+ solid tumors
Intervention Type
Drug
Intervention Name(s)
Oral repotrectinib (TPX-0005)
Other Intervention Name(s)
repotrectinib
Intervention Description
Oral repotrectinib (TPX-0005) capsules.
Primary Outcome Measure Information:
Title
Dose limiting toxicities (DLTs) (Phase 1)
Description
Define the dose limiting toxicities (DLTs) (Phase 1)
Time Frame
Within 28 days of the first repotrectinib dose
Title
Recommended Phase 2 Dose (RP2D) (Phase 1)
Description
To determine the RP2D (Phase 1)
Time Frame
Within 28 days of the last patient dosed in escalation
Title
Overall Response Rate (ORR) Phase 2
Description
To determine the confirmed ORR of repotrectinib (TPX-0005) as assessed by Blinded Independent Central Review (Phase 2)
Time Frame
Two to three years after first dose of repotrectinib dose
Secondary Outcome Measure Information:
Title
Maximum plasma concentration (CMAX) of repotrectinib (TPX-0005) (Phase 1)
Description
To determine the maximum plasma concentration (CMAX) of repotrectinib (TPX-0005)
Time Frame
Up to 72 hours post dose
Title
Area under the plasma concentration time curve (AUC) of repotrectinib (TPX-0005) (Phase 1)
Description
To determine the area under the plasma concentration time curve (AUC) of repotrectinib
Time Frame
Up to 72 hours post dose
Title
Area under the plasma concentration time curve (AUC) of repotrectinib under different food intake conditions(TPX-0005) (Phase 1)
Description
To determine the area under the plasma concentration time curve (AUC) of repotrectinib under different food intake conditions(TPX-0005) (Phase 1)
Time Frame
Up to 72 hours post dose
Title
Maximum plasma concentration (CMAX) of repotrectinib under different food intake conditions(TPX-0005) (Phase 1)
Description
To determine the maximum plasma concentration (CMAX) of repotrectinib under different food intake conditions(TPX-0005) (Phase 1)
Time Frame
Up to 72 hours post dose
Title
Area under the plasma concentration time curve (AUC) of midazolam(TPX-0005) (Phase 1)
Description
To determine the area under the plasma concentration time curve (AUC) of midazolam(TPX-0005) (Phase 1)
Time Frame
Up to 24 hours post dose
Title
Maximum plasma concentration (CMAX) of midazolam(TPX-0005) (Phase 1)
Description
To determine the maximum plasma concentration (CMAX) of midazolam(TPX-0005) (Phase 1)
Time Frame
Up to 24 hours post dose
Title
Plasma concentration of repotrectinib following administration at RP2D (Phase 2)
Description
To evaluate the plasma concentration of repotrectinib following administration at RP2D (Phase 2)
Time Frame
Pre dose and 4 hours post dose
Title
Preliminary objective response rate (ORR) (Phase 1)
Description
To determine the preliminary objective response rate (ORR) by Blinded Independent Central Review (BICR) (Phase 1)
Time Frame
Approximately three years
Title
Duration of response (DOR) (Phase 2)
Description
To determine the DOR of repotrectinib (TPX-0005) (Phase 2)
Time Frame
Approximately three years
Title
Clinical benefit rate (CBR) (Phase 2)
Description
To determine the CBR of repotrectinib (TPX-0005) (Phase 2)
Time Frame
Approximately three years
Title
Progression free survival (PFS) (Phase 2)
Description
To determine the PFS (Phase 2)
Time Frame
Approximately three years
Title
Overall survival (OS) (Phase 2)
Description
To determine the OS (Phase 2)
Time Frame
Approximately three years
Title
Intracranial objective response rate (Phase 2)
Description
To determine the intracranial objective response rate (Phase 2)
Time Frame
Approximately three years

10. Eligibility

Sex
All
Minimum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
PHASE 1 Key Inclusion Criteria: Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic solid tumor (including primary CNS tumors) (Stage IV, American Joint Committee on Cancer v.7) that harbors an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement by protocol specified tests. ECOG PS 0-1. Age ≥18 (or age ≥ 20 of age as required by local regulation). Capability to swallow capsules intact (without chewing, crushing, or opening). At least 1 measurable target lesion according to RECIST version 1.1. CNS-only measurable disease as defined by RECIST version 1.1 is allowed. Prior cytotoxic chemotherapy is allowed. Prior immunotherapy is allowed. Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 Grade less than or equal to 1. Patients with asymptomatic CNS metastases (treated or untreated) and/or asymptomatic leptomeningeal carcinomatosis are eligible to enroll if they satisfy the protocol specified criteria. Baseline laboratory values fulfilling the following requirements:Absolute neutrophils count (ANC) ≥1500/mm3 (1.5 × 109/L); Platelets (PLTs) ≥100,000/mm3 (100 × 109/L); Hemoglobin ≥ 9.0 g/dL transfusions are allowed; Serum creatinine or creatinine clearance Within normal limits or > 40 mL/min; Total serum bilirubin < 1.5 × ULN; Liver transaminases (ASTs/ALTs) < 2.5 × ULN; < 5 × ULN if liver metastases are present Alkaline phosphatase (ALP); < 2.5 × ULN; < 5 × ULN if liver and/or bone metastasis are present; Serum calcium, magnesium, and potassium Normal or CTCAE grade ≤ 1 with or without supplementation Life expectancy ≥ 3 months. PHASE 2 Key Inclusion Criteria Histologically or cytologically confirmed diagnosis of locally advanced, or metastatic solid tumor (including primary CNS tumors) that harbors a ROS1, or NTRK1-3 gene fusion. Subject must have a documented ROS1 or NTRK1-3 gene fusion determined by tissue-based local testing using either: a next-generation sequencing (NGS) or quantitative polymerase chain reaction (qPCR) test will be accepted to determine molecular eligibility. • Adequate tumor tissue needs to be sent to the Sponsor designated central diagnostic laboratory for retrospective confirmation by a central diagnostic laboratory test selected by the Sponsor. OR a fluorescence in situ hybridization (FISH) test AND prospective confirmation of fusion status by a central diagnostic laboratory test selected by the Sponsor PRIOR to enrollment will be accepted to determine molecular eligibility. Adequate tumor tissue must be sent to the Sponsor designated central diagnostic laboratory for prospective confirmation by a central diagnostic laboratory test selected by the Sponsor PRIOR to enrollment. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1. Age ≥12 (or age ≥ 20 as required by local regulation). Willing and able to provide written institutional review board (IRB)/institutional ethics committee-approved Informed Consent or an Assent signed by a parent or legal guardian for subjects age 12 to 17. At least 1 measurable target lesion according to RECIST (v1.1) prospectively confirmed by Blinded Independent Central Radiology Review (BICR), selected by Sponsor, PRIOR to enrollment. Subjects with CNS-only measurable disease ≥10 mm as defined by RECIST (v1.1) are eligible. Subjects with advanced solid tumors harboring ROS1, NTRK1, NTRK2, or NTRK3 rearrangement will be assigned into 6 distinct expansion (EXP) cohorts provided all inclusion and exclusion criteria are met. i. EXP-1: ROS1 TKI-naïve ROS1+ NSCLC ii. EXP-2: 1 Prior ROS1 TKI and 1 Platinum based chemo ROS1+ NSCLC iii. EXP-3: 2 Prior ROS1 TKIs ROS1+ NSCLC (No Chemo or IO) iv. EXP-4: 1 Prior ROS1 TKI ROS1+ NSCLC (No Chemo or IO) v. EXP-5: TRK TKI-naïve NTRK+ solid tumors vi. EXP-6: TRK TKI-pretreated NTRK+ solid tumors Subjects with asymptomatic CNS metastases (treated or untreated) and/or asymptomatic leptomeningeal carcinomatosis are eligible to enroll if they satisfy the protocol specified criteria. Baseline laboratory values fulfilling the following requirements:Absolute neutrophils count (ANC) ≥1500/mm3 (1.5 × 109/L); Platelets (PLTs) ≥100,000/mm3 (100 × 109/L); Hemoglobin ≥ 9.0 g/dL transfusions are allowed; Serum creatinine or creatinine clearance > 40 mL/min; Total serum bilirubin < 1.5 × ULN; Liver transaminases (ASTs/ALTs) < 2.5 × ULN; < 5 × ULN if liver metastases are present Alkaline phosphatase (ALP); < 2.5 × ULN; < 5 × ULN if liver and/or bone metastasis are present; Serum calcium, magnesium, and potassium Normal or CTCAE grade ≤ 1 with or without supplementation Life expectancy ≥ 3 months. Key Exclusion Criteria PHASE 1 and PHASE 2 Concurrent participation in another therapeutic clinical trial. Symptomatic brain metastases or leptomeningeal involvement. History of previous cancer, except for squamous cell or basal-cell carcinoma of the skin, or any in situ carcinoma that has been completely resected, requiring therapy within the previous 2 years. Major surgery within 4 weeks of start of repotrectinib treatment. Radiation therapy (except palliative to relieve bone pain) within 2 weeks of study entry. Palliative radiation (≤10 fractions) must have been completed at least 48 hours prior to study entry Clinically significant cardiovascular disease (either active or within 6 months prior to enrollment): myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure (New York Heart Association Classification Class ≥ II), cerebrovascular accident or transient ischemic attack, symptomatic bradycardia, requirement for anti-arrhythmic medication. Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥2 Any of the following cardiac criteria: Mean resting corrected QT interval (ECG interval measured from the onset of the QRS complex to the end of the T wave) for heart rate (QTcF) > 470 msec obtained from 3 ECGs, using the screening clinic ECG machine-derived QTc value Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block, second degree heart block, PR interval > 250 msec) Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or any concomitant medication known to prolong the QT interval. Known active infections (bacterial, fungal, viral including HIV positivity). Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact drug absorption. Peripheral neuropathy of CTCAE ≥grade 2. History of extensive, disseminated, bilateral, or presence of CTCAE grade 3 or 4 interstitial fibrosis or interstitial lung disease including a history of pneumonitis, hypersensitivity pneumonitis, interstitial pneumonia, interstitial lung disease, obliterative bronchiolitis, and pulmonary fibrosis. Subjects with history of prior radiation pneumonitis are not excluded.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
BMS Study Connect Contact Center www.BMSStudyConnect.com
Phone
855-907-3286
Email
Clinical.Trials@bms.com
First Name & Middle Initial & Last Name or Official Title & Degree
First line of the email MUST contain the NCT# and Site #.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bristol-Myers Squibb
Organizational Affiliation
Bristol-Myers Squibb
Official's Role
Study Director
Facility Information:
Facility Name
City Of Hope
City
Duarte
State/Province
California
ZIP/Postal Code
91010
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nishan Tchekmedyian, Site 2129
Phone
562-590-0345
Facility Name
Adventist Health Glendale
City
Glendale
State/Province
California
ZIP/Postal Code
91206
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mihran Shirinian, Site 2120
Phone
818-409-6687
Facility Name
UC San Diego Health
City
La Jolla
State/Province
California
ZIP/Postal Code
92093
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lyudmila Bazhenova, Site 2114
Phone
866-773-2703
Facility Name
Pacific Shores Medical Group
City
Long Beach
State/Province
California
ZIP/Postal Code
90813
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nishan Tchekmedyian, Site 2121
Phone
562-590-0345
Facility Name
UC Irvine Medical Center
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Misako Nagasaka, Site 2101
Phone
714-456-5153
Facility Name
St Joseph Heritage Healthcare
City
Santa Rosa
State/Province
California
ZIP/Postal Code
95403
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ian Anderson, Site 2126
Facility Name
University Of Colorado Denver
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ross Camidge, Site 2103
Phone
720-848-0449
Facility Name
Georgetown University Medical Center - Lombardi Comprehensive Cancer Center
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20007
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stephen Liu, Site 2106
Phone
202-444-2223
Facility Name
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
City
Washington
State/Province
District of Columbia
ZIP/Postal Code
20016
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Benjamin Levy, Site 2110
Phone
347-324-6573
Facility Name
Memorial Healthcare System
City
Hollywood
State/Province
Florida
ZIP/Postal Code
33021
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Luis Raez, Site 2128
Phone
954-265-4325
Facility Name
Moffitt Cancer Center
City
Tampa
State/Province
Florida
ZIP/Postal Code
33612
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Benjamin Creelan, Site 2113
Phone
813-745-6895
Facility Name
University Cancer and Blood Center
City
Athens
State/Province
Georgia
ZIP/Postal Code
30607
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
PETROS NIKOLINAKOS, Site 2139
Phone
706-353-2990
Facility Name
Colombus Regional Research Institute
City
Columbus
State/Province
Georgia
ZIP/Postal Code
31904
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Andrew Pippas, Site 2134
Phone
706-660-6449
Facility Name
University of Chicago
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60637
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christine Bestvina, Site 2125
Phone
773-702-4400
Facility Name
Illinois Cancer Care
City
Peoria
State/Province
Illinois
ZIP/Postal Code
61615
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Greg Gerstner, Site 2142
Facility Name
University of Maryland Medical Center
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21210
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Katherine Scilla, Site 2133
Phone
410-328-6373
Facility Name
Massachusetts General Hospital,
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jessica Lin, Site 2104
Phone
617-724-4000
Facility Name
Dana Farber Cancer Institute.
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mark Awad, Site 2131
Phone
617-632-3468
Facility Name
University Of Michigan
City
Ann Arbor
State/Province
Michigan
ZIP/Postal Code
48109
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Angel Qin, Site 2105
Facility Name
Karmanos Cancer Institute
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48201
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dipesh Uprety, Site 2111
Phone
215-285-2261
Facility Name
Henry Ford Transplant Institute
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202-2608
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shirish Gadgeel, Site 2140
Phone
313-399-0508
Facility Name
Regions Hospital - Cancer Care Center
City
Saint Paul
State/Province
Minnesota
ZIP/Postal Code
55101
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Arkadiusz Dudek, Site 2132
Phone
31299615816512543321
Facility Name
Central Care Cancer Center
City
Bolivar
State/Province
Missouri
ZIP/Postal Code
65613
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Leonid Shunyakov, Site 2147
Phone
417-326-7200
Facility Name
Washington University Infusion Center Pharmacy
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Brian Van Tine, Site 2115
Phone
314-747-3096
Facility Name
Rutgers Cancer Institute of New Jersey
City
New Brunswick
State/Province
New Jersey
ZIP/Postal Code
08901
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Scott Moerdler, Site 2122
Phone
000-000-0000
Facility Name
Laura & Isaac Perlmutter Cancer Center
City
New York
State/Province
New York
ZIP/Postal Code
10016
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Vamsidhar Velcheti, Site 2117
Phone
216-903-4153
Facility Name
Memorial Sloan Kettering Cancer Center
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alexander Drilon, Site 2102
Phone
646-888-4206
Facility Name
Southeastern Medical Oncology Center
City
Goldsboro
State/Province
North Carolina
ZIP/Postal Code
27534
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Samer Kasbari, Site 2144
Phone
919-580-0000
Facility Name
Gabrail Cancer Center
City
Canton
State/Province
Ohio
ZIP/Postal Code
44718
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nashat Gabrail, Site 2112
Phone
330-417-8231
Facility Name
Trihealth Cancer Institute
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45220
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Faisal Adhami, MD, Site 2143
Facility Name
Cleveland Clinic Main Campus
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pete Anderson, Site 2109
Facility Name
The Ohio State University Wexner Medical Center
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dwight Owen, Site 2123
Phone
614-293-6401
Facility Name
Fox Chase Cancer Center
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19111-2497
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jessica Bauman, Site 2108
Phone
215-728-5673
Facility Name
Baptist Memorial Hospital Baptist Cancer Center
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38120
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Philip Lammers, Site 2148
Facility Name
UT Southwestern Medical Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Syed Kazmi, Site 2130
Phone
214-648-5368
Facility Name
MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yasir Elamin, Site 2138
Facility Name
Oncology Consultants, P.A.
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Julio Peguero, Site 2127
Phone
713-600-0913
Facility Name
Lumi Research
City
Kingwood
State/Province
Texas
ZIP/Postal Code
77339
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Saleha Sajid, Site 2146
Phone
832-553-3661
Facility Name
Virginia Cancer Specialists, PC
City
Fairfax
State/Province
Virginia
ZIP/Postal Code
22031
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Alexander Spira, Site 2137
Phone
703-280-5390
Facility Name
University of Washington-Seattle Cancer Care Alliance
City
Seattle
State/Province
Washington
ZIP/Postal Code
98109
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Christina Baik, Site 2107
Facility Name
ThedaCare
City
Appleton
State/Province
Wisconsin
ZIP/Postal Code
54911
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Matthias Weiss, Site 2145
Facility Name
Local Institution - 6102
City
Camperdown
State/Province
New South Wales
ZIP/Postal Code
2050
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6102
Facility Name
Local Institution - 6103
City
Adelaide
State/Province
South Australia
ZIP/Postal Code
5042
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6103
Facility Name
Local Institution - 6101
City
Melbourne
State/Province
Victoria
ZIP/Postal Code
3000
Country
Australia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6101
Facility Name
Local Institution - 4802
City
Antwerp
ZIP/Postal Code
2650
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4802
Facility Name
Local Institution - 4801
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4801
Facility Name
Local Institution - 2202
City
Edmonton
State/Province
Alberta
ZIP/Postal Code
T6G 1Z2
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 2202
Facility Name
Local Institution - 2205
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V5Z 4E7
Country
Canada
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 2205
Facility Name
Local Institution - 2201
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 2M9
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 2201
Facility Name
Local Institution - 6503
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 2M9
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6503
Facility Name
Local Institution - 2203
City
Ontario
ZIP/Postal Code
L6R 37R
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 2203
Facility Name
Local Institution - 2204
City
Ottawa
ZIP/Postal Code
K1H 8L6
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 2204
Facility Name
Local Institution - 6702
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100021
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6702
Facility Name
Local Institution - 6703
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100142
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6703
Facility Name
Local Institution - 6736
City
Daping
State/Province
Chongqing
ZIP/Postal Code
00000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6736
Facility Name
Local Institution - 6719
City
Fuzhou
State/Province
Fujian
ZIP/Postal Code
000000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6719
Facility Name
Local Institution - 6708
City
Xiamen
State/Province
Fujian
ZIP/Postal Code
361003
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6708
Facility Name
Local Institution - 6733
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510120
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6733
Facility Name
Local Institution - 6747
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510120
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6747
Facility Name
Local Institution - 6505
City
Shenzhen
State/Province
Guangdong
ZIP/Postal Code
518053
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6505
Facility Name
Local Institution - 6722
City
Harbin
State/Province
Heilongjiang
ZIP/Postal Code
150081
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6722
Facility Name
Local Institution - 6504
City
Shatin
State/Province
Hong Kong
ZIP/Postal Code
999077
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6504
Facility Name
Local Institution - 6705
City
Changsha
State/Province
Hunan
ZIP/Postal Code
410011
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6705
Facility Name
Local Institution - 6718
City
Changsha
State/Province
Hunan
ZIP/Postal Code
410013
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6718
Facility Name
Local Institution - 6748
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210008
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6748
Facility Name
Local Institution - 6732
City
Xuzhou City
State/Province
Jiangsu
ZIP/Postal Code
00000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6732
Facility Name
Local Institution - 6714
City
Changchun
State/Province
Jilin
ZIP/Postal Code
130021
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6714
Facility Name
Local Institution - 6742
City
Shenyang
State/Province
Liaoning
ZIP/Postal Code
110801
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6742
Facility Name
Local Institution - 6754
City
Xi'an
State/Province
Shan3xi
ZIP/Postal Code
710038
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6754
Facility Name
Local Institution - 6749
City
Taiyuan
State/Province
Shanxi
ZIP/Postal Code
030032
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6749
Facility Name
Local Institution - 6728
City
Chengdu City
State/Province
Sichuan
ZIP/Postal Code
00000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6728
Facility Name
Local Institution - 6716
City
Chongqing
State/Province
Sichuan
ZIP/Postal Code
400030
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6716
Facility Name
Local Institution - 6725
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310016
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6725
Facility Name
Local Institution - 6721
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310022
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6721
Facility Name
Local Institution - 6717
City
Changchun City
ZIP/Postal Code
000000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6717
Facility Name
Local Institution - 6720
City
Changchun City
ZIP/Postal Code
000000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6720
Facility Name
Local Institution - 6734
City
Changsha
ZIP/Postal Code
00000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6734
Facility Name
Local Institution - 6724
City
Chengdu
ZIP/Postal Code
00000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6724
Facility Name
Local Institution - 6712
City
Hangzhou
ZIP/Postal Code
310003
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6712
Facility Name
Local Institution - 6704
City
Hefei
ZIP/Postal Code
230001
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6704
Facility Name
Local Institution - 6701
City
Shanghai
ZIP/Postal Code
200030
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6701
Facility Name
Local Institution - 6709
City
Shanghai
ZIP/Postal Code
200030
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6709
Facility Name
Local Institution - 6727
City
Weifang City
ZIP/Postal Code
00000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6727
Facility Name
Local Institution - 6710
City
Wuhan
ZIP/Postal Code
000000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6710
Facility Name
Local Institution - 6715
City
Zhengzhou
ZIP/Postal Code
00000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6715
Facility Name
Local Institution - 4901
City
Copenhagen
ZIP/Postal Code
2100
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4901
Facility Name
Local Institution - 4201
City
Marseille
State/Province
Bouches-du-Rhône
ZIP/Postal Code
13005
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4201
Facility Name
Local Institution - 4207
City
Brest
ZIP/Postal Code
29200
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4207
Facility Name
Local Institution - 4204
City
Dijon Cedex
ZIP/Postal Code
21079
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4204
Facility Name
Local Institution - 4206
City
Grenoble Cedex 9
ZIP/Postal Code
38043
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4206
Facility Name
Local Institution - 4205
City
Nice
ZIP/Postal Code
06189
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4205
Facility Name
Local Institution - 4208
City
Poitiers
ZIP/Postal Code
86000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4208
Facility Name
Local Institution - 4203
City
St Mande
ZIP/Postal Code
94163
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4203
Facility Name
Local Institution - 4202
City
Villejuif
ZIP/Postal Code
98405
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4202
Facility Name
Local Institution - 4704
City
Berlin
ZIP/Postal Code
13125
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4704
Facility Name
Local Institution - 4703
City
Dresden
ZIP/Postal Code
01307
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4703
Facility Name
Local Institution - 4702
City
Heidelberg
ZIP/Postal Code
69120
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4702
Facility Name
Local Institution - 4701
City
Koln
ZIP/Postal Code
50937
Country
Germany
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4701
Facility Name
Local Institution - 6502
City
Hong Kong
ZIP/Postal Code
0
Country
Hong Kong
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6502
Facility Name
Local Institution - 6501
City
Hong Kong
Country
Hong Kong
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6501
Facility Name
Local Institution - 5101
City
Budapest
ZIP/Postal Code
1083
Country
Hungary
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 5101
Facility Name
Local Institution - 5103
City
Budapest
ZIP/Postal Code
1121
Country
Hungary
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 5103
Facility Name
Local Institution - 4301
City
Milano
State/Province
MI
ZIP/Postal Code
20133
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4301
Facility Name
Local Institution - 4306
City
Milano
ZIP/Postal Code
20122
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4306
Facility Name
Local Institution - 4307
City
Palermo
ZIP/Postal Code
90146
Country
Italy
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4307
Facility Name
Local Institution - 4303
City
Pordenone
ZIP/Postal Code
33081
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4303
Facility Name
Local Institution - 4305
City
Reggio Emilia
ZIP/Postal Code
42123
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4305
Facility Name
Local Institution - 4308
City
Roma
ZIP/Postal Code
144
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4308
Facility Name
Local Institution - 4302
City
Terni
ZIP/Postal Code
05100
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4302
Facility Name
Local Institution - 6609
City
Toon
State/Province
Ehime
ZIP/Postal Code
791-0295
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6609
Facility Name
Local Institution - 6607
City
Sapporo-shi
State/Province
Hokkaido
ZIP/Postal Code
0608648
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6607
Facility Name
Local Institution - 6603
City
Yokohama
State/Province
Kanagawa
ZIP/Postal Code
2418515
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6603
Facility Name
Local Institution - 6605
City
Osaka-shi
State/Province
Osaka
ZIP/Postal Code
5340021
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6605
Facility Name
Local Institution - 6604
City
Chuo-ku
State/Province
Tokyo
ZIP/Postal Code
1040045
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6604
Facility Name
Local Institution - 6606
City
Yonago
State/Province
Tottori
ZIP/Postal Code
683-8504
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6606
Facility Name
Local Institution - 6601
City
Kashiwa
ZIP/Postal Code
277-8577
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6601
Facility Name
Local Institution - 6608
City
Nagoya-shi
ZIP/Postal Code
466-8560
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6608
Facility Name
Local Institution - 6602
City
Osaka
ZIP/Postal Code
5418567
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6602
Facility Name
Local Institution - 6305
City
Seoul
ZIP/Postal Code
05505
Country
Korea, Democratic People's Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6305
Facility Name
Local Institution - 6308
City
Hwasun-eup, Hwasun-gun
State/Province
Jeonnam
ZIP/Postal Code
519-763
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6308
Facility Name
Local Institution - 6301
City
Seoul
State/Province
Seoul-teukbyeolsi [Seoul]
ZIP/Postal Code
03080
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6301
Facility Name
Local Institution - 6303
City
Seoul
State/Province
Seoul-teukbyeolsi [Seoul]
ZIP/Postal Code
06351
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6303
Facility Name
Local Institution - 6306
City
Cheongju-si
ZIP/Postal Code
28644
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6306
Facility Name
Local Institution - 6302
City
Seoul
ZIP/Postal Code
03722
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6302
Facility Name
Local Institution - 6307
City
Seoul
ZIP/Postal Code
05030
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6307
Facility Name
Local Institution - 6304
City
Seoul
ZIP/Postal Code
06591
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6304
Facility Name
Local Institution - 4502
City
Amsterdam
ZIP/Postal Code
1066 CX
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4502
Facility Name
Local Institution - 4501
City
Groningen
ZIP/Postal Code
9713 GZ
Country
Netherlands
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4501
Facility Name
Local Institution - 4601
City
Gdańsk
ZIP/Postal Code
80-214
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4601
Facility Name
Local Institution - 4604
City
Lublin
ZIP/Postal Code
20-609
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4604
Facility Name
Local Institution - 4605
City
Poznań
ZIP/Postal Code
60-693
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4605
Facility Name
Local Institution - 4603
City
Szczecin
ZIP/Postal Code
70-784
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4603
Facility Name
Local Institution - 4602
City
Warszawa
ZIP/Postal Code
02-781
Country
Poland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4602
Facility Name
Local Institution - 6401
City
Singapore
ZIP/Postal Code
119074
Country
Singapore
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6401
Facility Name
Local Institution - 6402
City
Singapore
ZIP/Postal Code
169610
Country
Singapore
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6402
Facility Name
Local Institution - 4102
City
Barcelona
ZIP/Postal Code
08028
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4102
Facility Name
Local Institution - 4101
City
Barcelona
ZIP/Postal Code
8035
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4101
Facility Name
Local Institution - 4106
City
Madrid
ZIP/Postal Code
28033
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4106
Facility Name
Local Institution - 4104
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4104
Facility Name
Local Institution - 4103
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4103
Facility Name
Local Institution - 4105
City
Madrid
ZIP/Postal Code
28050
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4105
Facility Name
Local Institution - 4108
City
Pamplona
ZIP/Postal Code
31008
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4108
Facility Name
Local Institution - 4107
City
Valencia
ZIP/Postal Code
46009
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4107
Facility Name
Local Institution - 6201
City
Taiepi
ZIP/Postal Code
100
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6201
Facility Name
Local Institution - 6203
City
Tainan
ZIP/Postal Code
704
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6203
Facility Name
Local Institution - 6202
City
Taipei
ZIP/Postal Code
10449
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 6202
Facility Name
Local Institution - 4401
City
London
ZIP/Postal Code
SW3 6JJ
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4401
Facility Name
Local Institution - 4402
City
London
ZIP/Postal Code
W12 OHS
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4402
Facility Name
Local Institution - 4404
City
London
ZIP/Postal Code
W1G 6AD
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4404
Facility Name
Local Institution - 4403
City
Manchester
ZIP/Postal Code
M20 4BX
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4403
Facility Name
Local Institution - 4405
City
Sutton
ZIP/Postal Code
SM2 5PT
Country
United Kingdom
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Site 4405

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
There are no plans to share individual participant data with other researchers.
Citations:
PubMed Identifier
32269053
Citation
Yun MR, Kim DH, Kim SY, Joo HS, Lee YW, Choi HM, Park CW, Heo SG, Kang HN, Lee SS, Schoenfeld AJ, Drilon A, Kang SG, Shim HS, Hong MH, Cui JJ, Kim HR, Cho BC. Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naive and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 Jul 1;26(13):3287-3295. doi: 10.1158/1078-0432.CCR-19-2777. Epub 2020 Apr 8.
Results Reference
derived
PubMed Identifier
30093503
Citation
Drilon A, Ou SI, Cho BC, Kim DW, Lee J, Lin JJ, Zhu VW, Ahn MJ, Camidge DR, Nguyen J, Zhai D, Deng W, Huang Z, Rogers E, Liu J, Whitten J, Lim JK, Stopatschinskaja S, Hyman DM, Doebele RC, Cui JJ, Shaw AT. Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. Cancer Discov. 2018 Oct;8(10):1227-1236. doi: 10.1158/2159-8290.CD-18-0484. Epub 2018 Aug 9.
Results Reference
derived
Links:
URL
https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html
Description
BMS Clinical Trial Information
URL
https://www.bmsstudyconnect.com/s/US/English/USenHome
Description
BMS Clinical Trial Patient Recruiting
URL
https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm
Description
FDA Safety Alerts and Recalls

Learn more about this trial

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

We'll reach out to this number within 24 hrs